8-K: Solidion Technology Restates Q2 2025 Financials

Solidion Technology, Inc. announced that its Q2 2025 interim financial statements should no longer be relied upon due to identified errors in warrant valuation and diluted EPS calculations.

Summary

• Solidion Technology, Inc. (the "Company") has concluded that its interim financial statements for the period ended June 30, 2025, included in its Quarterly Report on Form 10-Q, should no longer be relied upon.
• This non-reliance also extends to any prior earnings releases and investor communications that discussed the Affected Financial Information.
• Errors were identified in the reported number of Series A Warrants outstanding and their related fair value measurement as of June 30, 2025, and for the threeand six-month periods ended June 30, 2025.
• The Company determined that 810,389 Series A Warrants should have been subject to fair value measurement, and the corresponding fair value as of June 30, 2025, was understated by $2,260,650.
• Additionally, errors were found in the number of Series A and Series C shares included in the diluted earnings per share (EPS) calculations for the six-month period ended June 30, 2025.
• Specifically, 576,540 Series A and 1,715,677 Series C common stock equivalents should have been included in the diluted EPS calculation.
• The Company plans to file Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2025, to amend and restate the original filing.
• The Company's management and Audit Committee have discussed these matters with Deloitte & Touche LLP, the independent registered public accounting firm.

Sentiment

Score: 3

Explanation: The filing indicates significant accounting errors requiring a restatement of previously issued financial statements, which is a negative event for investor confidence and corporate governance. The understatement of warrant fair value and miscalculation of diluted EPS are material issues.

Negatives

• The Company's previously issued interim financial statements for Q2 2025 can no longer be relied upon, indicating material errors.
• The fair value of Series A Warrants as of June 30, 2025, was understated by $2,260,650.
• The diluted EPS calculations for the six months ended June 30, 2025, were incorrect due to the exclusion of 576,540 Series A and 1,715,677 Series C common stock equivalents.
• The need for a restatement can lead to a loss of investor confidence and potential scrutiny from regulatory bodies.

Risks

• Loss of investor confidence due to unreliable financial reporting.
• Potential negative impact on the Company's stock price.
• Increased scrutiny from regulatory authorities, including the SEC.
• Reputational damage stemming from financial misstatements.
• Potential for delays in future financial filings as the Company addresses these issues.

Future Outlook

The Company will file Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2025, to amend and restate the original filing, including restated financial information and other related modifications. This will occur prior to the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Management Comments

• The Chief Financial Officer, after consultation with the Company's Audit Committee, concluded that the Company's previously issued interim financial statements as of and for the period ended June 30, 2025, should no longer be relied upon.

Industry Context

This announcement pertains to company-specific accounting errors and does not directly reflect broader industry trends. However, financial restatements can impact investor perception of the company's internal controls and financial reporting quality, which is a critical aspect across all industries.

Corporate Governance

Stakeholder Impact

• Shareholders: May experience a decrease in share price due to loss of confidence in financial reporting accuracy and potential uncertainty regarding future financial performance.
• Investors: Will need to re-evaluate their investment thesis based on restated financials and potential concerns about internal controls.
• Regulatory Authorities: The SEC will likely scrutinize the restatement and the Company's remediation efforts.

Next Steps

• The Company will file Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2025, to amend and restate the original filing.
• The restated filing will include corrected financial information and other related modifications.
• The amended filing will occur prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Key Dates

Recommendation

The identified accounting errors and subsequent restatement of Q2 2025 financials introduce significant uncertainty and raise concerns about the Company's internal controls and financial reporting accuracy. While the Company is taking steps to correct the issues, the immediate impact is negative. A 'hold' recommendation is prudent, advising investors to await the restated financials and further clarity on the root causes and remediation efforts before making definitive investment decisions. A 'sell' might be too aggressive without more information on the underlying business health, but a 'buy' is unwarranted given the current uncertainty.

Keywords

Solidion Technology, STI, SEC filing, 8-K, financial restatement, Q2 2025, interim financial statements, warrants, fair value measurement, diluted EPS, earnings per share, accounting errors, Nasdaq